相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discovering Novel α-aminoacyl-Containing Proline Derivatives with Potent and Selective Inhibitory Activity Against Dipeptidyl Peptidase IV: Design, Synthesis, Biological Evaluation, and Molecular Modeling
Xiaodong Zhang et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2012)
REFMAC5 for the refinement of macromolecular crystal structures
Garib N. Murshudov et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Ruthenium-catalyzed azide-alkyne cycloaddition: Scope and mechanism
Brant C. Boren et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats
Jutta Schade et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2008)
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
Matthias Eckhardt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes
J. Zhang et al.
DIABETOLOGIA (2007)
Phaser crystallographic software
Airlie J. McCoy et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)
Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
Jun Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Molecular recognition of ligands in dipeptidyl peptidase IV
Bernd Kuhn et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
GR Lankas et al.
DIABETES (2005)
Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
DJ Augeri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Glucagon-like peptide-1: The basis of a new class of treatment for type 2 diabetes
LB Knudsen
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Multiparametric scaling of diffraction intensities
Z Otwinowski et al.
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES (2003)
Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis
DJ Drucker
MOLECULAR ENDOCRINOLOGY (2003)
1-[2-[(5-cyanopyridin-2-yl)amino]-ethylamino]acetyl-2-(S)-pyrrolidine-carbonitrile:: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
EB Villhauer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
分享论文
